Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 11 | 2024 | 128 | 1.740 |
Why?
|
| Eflornithine | 5 | 2023 | 18 | 0.790 |
Why?
|
| Behavioral Sciences | 1 | 2020 | 2 | 0.790 |
Why?
|
| Leadership | 1 | 2020 | 63 | 0.740 |
Why?
|
| Clergy | 1 | 2019 | 12 | 0.700 |
Why?
|
| Terminal Care | 1 | 2019 | 47 | 0.670 |
Why?
|
| Health Personnel | 1 | 2019 | 200 | 0.600 |
Why?
|
| Sodium-Potassium-Chloride Symporters | 2 | 2004 | 5 | 0.480 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 756 | 0.470 |
Why?
|
| Bronchi | 2 | 2004 | 45 | 0.460 |
Why?
|
| Survivors | 1 | 2013 | 126 | 0.440 |
Why?
|
| Tretinoin | 3 | 2008 | 50 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2024 | 133 | 0.360 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 18 | 0.360 |
Why?
|
| Health Behavior | 1 | 2013 | 491 | 0.360 |
Why?
|
| Sp3 Transcription Factor | 2 | 2008 | 8 | 0.340 |
Why?
|
| Neoplasms | 2 | 2021 | 1033 | 0.340 |
Why?
|
| Child | 8 | 2024 | 2875 | 0.330 |
Why?
|
| Immunoglobulins | 1 | 2008 | 36 | 0.330 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 287 | 0.300 |
Why?
|
| Genes, myc | 2 | 2003 | 28 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 178 | 0.290 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2004 | 84 | 0.280 |
Why?
|
| Humans | 20 | 2024 | 34853 | 0.250 |
Why?
|
| Blood Preservation | 1 | 2004 | 6 | 0.250 |
Why?
|
| Blood Banks | 1 | 2004 | 9 | 0.250 |
Why?
|
| Blood Specimen Collection | 1 | 2004 | 12 | 0.250 |
Why?
|
| Nervous System Neoplasms | 1 | 2003 | 2 | 0.240 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2003 | 2 | 0.240 |
Why?
|
| Fetal Blood | 1 | 2004 | 47 | 0.240 |
Why?
|
| Medulloblastoma | 1 | 2023 | 2 | 0.240 |
Why?
|
| Cerebellar Neoplasms | 1 | 2023 | 3 | 0.240 |
Why?
|
| Trachea | 1 | 2002 | 19 | 0.230 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 51 | 0.220 |
Why?
|
| Fibroblasts | 1 | 2004 | 252 | 0.220 |
Why?
|
| Immune Evasion | 1 | 2021 | 16 | 0.210 |
Why?
|
| Vault Ribonucleoprotein Particles | 1 | 2020 | 1 | 0.200 |
Why?
|
| Chromosome Disorders | 1 | 2020 | 10 | 0.200 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2020 | 7 | 0.200 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2020 | 25 | 0.190 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 29 | 0.190 |
Why?
|
| Patient Care Team | 1 | 2020 | 44 | 0.190 |
Why?
|
| Autistic Disorder | 1 | 2020 | 37 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2020 | 97 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 209 | 0.180 |
Why?
|
| Health Resources | 1 | 2019 | 32 | 0.170 |
Why?
|
| Child, Preschool | 5 | 2021 | 1318 | 0.170 |
Why?
|
| Pediatrics | 1 | 2019 | 66 | 0.170 |
Why?
|
| Faculty | 1 | 2019 | 82 | 0.170 |
Why?
|
| Curriculum | 1 | 2019 | 237 | 0.150 |
Why?
|
| Mutation | 1 | 2021 | 1023 | 0.150 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 114 | 0.150 |
Why?
|
| Polyamines | 1 | 2015 | 28 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2008 | 420 | 0.120 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2013 | 52 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2008 | 834 | 0.120 |
Why?
|
| Hawaii | 2 | 2013 | 1878 | 0.110 |
Why?
|
| Phenotype | 1 | 2015 | 650 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2020 | 47 | 0.110 |
Why?
|
| Prognosis | 3 | 2021 | 707 | 0.100 |
Why?
|
| Cell Survival | 2 | 2004 | 818 | 0.100 |
Why?
|
| Phosphoproteins | 1 | 2012 | 154 | 0.100 |
Why?
|
| Motor Activity | 1 | 2013 | 393 | 0.100 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2012 | 184 | 0.100 |
Why?
|
| Adolescent | 3 | 2021 | 5035 | 0.100 |
Why?
|
| Recurrence | 2 | 2023 | 125 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 781 | 0.090 |
Why?
|
| Female | 6 | 2021 | 19873 | 0.090 |
Why?
|
| Survival Rate | 2 | 2021 | 310 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2013 | 490 | 0.090 |
Why?
|
| Young Adult | 2 | 2021 | 4012 | 0.080 |
Why?
|
| Etoposide | 2 | 2020 | 21 | 0.080 |
Why?
|
| Cell Movement | 1 | 2012 | 545 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 52 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 126 | 0.080 |
Why?
|
| Male | 5 | 2021 | 18870 | 0.080 |
Why?
|
| Diet | 1 | 2013 | 747 | 0.080 |
Why?
|
| Protein Transport | 1 | 2008 | 286 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 162 | 0.070 |
Why?
|
| Smoking | 1 | 2013 | 903 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2128 | 0.070 |
Why?
|
| Infant | 2 | 2021 | 1014 | 0.070 |
Why?
|
| Bumetanide | 1 | 2004 | 3 | 0.060 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2004 | 4 | 0.060 |
Why?
|
| Furosemide | 1 | 2004 | 9 | 0.060 |
Why?
|
| G1 Phase | 1 | 2004 | 32 | 0.060 |
Why?
|
| Blood Cells | 1 | 2004 | 8 | 0.060 |
Why?
|
| S Phase | 1 | 2004 | 36 | 0.060 |
Why?
|
| Diuretics | 1 | 2004 | 49 | 0.060 |
Why?
|
| Washington | 1 | 2004 | 28 | 0.060 |
Why?
|
| Tissue Donors | 1 | 2004 | 43 | 0.060 |
Why?
|
| Blood Donors | 1 | 2004 | 17 | 0.060 |
Why?
|
| Cell Count | 1 | 2004 | 129 | 0.060 |
Why?
|
| Propensity Score | 1 | 2023 | 40 | 0.060 |
Why?
|
| Biological Transport | 1 | 2004 | 175 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 1349 | 0.060 |
Why?
|
| Nifurtimox | 1 | 2023 | 1 | 0.060 |
Why?
|
| Topotecan | 1 | 2023 | 4 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 1 | 2003 | 44 | 0.060 |
Why?
|
| Cell Division | 1 | 2004 | 296 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 52 | 0.060 |
Why?
|
| Feasibility Studies | 1 | 2004 | 196 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 35 | 0.060 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 164 | 0.060 |
Why?
|
| Fetus | 1 | 2002 | 103 | 0.050 |
Why?
|
| Registries | 1 | 2004 | 330 | 0.050 |
Why?
|
| Tissue Distribution | 1 | 2002 | 197 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2022 | 44 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2022 | 91 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2020 | 3 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2020 | 8 | 0.050 |
Why?
|
| Cytarabine | 1 | 2020 | 8 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 201 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 52 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 859 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2004 | 1442 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 234 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2003 | 522 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2022 | 628 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2021 | 964 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 841 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2003 | 653 | 0.040 |
Why?
|
| Apoptosis | 1 | 2004 | 1317 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2022 | 1961 | 0.040 |
Why?
|
| Ornithine Decarboxylase | 1 | 2015 | 10 | 0.030 |
Why?
|
| Safety | 1 | 2015 | 48 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2012 | 24 | 0.030 |
Why?
|
| COS Cells | 1 | 2012 | 62 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2012 | 21 | 0.030 |
Why?
|
| Integrins | 1 | 2012 | 49 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2012 | 56 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 90 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2012 | 209 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2012 | 146 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 913 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1152 | 0.020 |
Why?
|
| Adult | 1 | 2021 | 11034 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2004 | 7 | 0.020 |
Why?
|
| Public Policy | 1 | 2004 | 31 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2004 | 66 | 0.020 |
Why?
|
| Neurofibromin 1 | 1 | 2003 | 2 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2003 | 45 | 0.010 |
Why?
|
| Drosophila | 1 | 2003 | 133 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 480 | 0.010 |
Why?
|
| Animals | 2 | 2012 | 14307 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 932 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 484 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1490 | 0.010 |
Why?
|
| United States | 1 | 2004 | 3894 | 0.010 |
Why?
|